2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, (CAR)-T Cell Therapies, Women’s Health, Adverse Events, Biological Processes, Pathogenesis, Genomics, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Thrombocytopenias, Thrombotic Disorders, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Non-Hodgkin Lymphoma, Research, APL, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Pregnant, Animal Model
PAPER

1289 Baseline hemostatic and endothelial biomarkers are associated with thrombohemorrhagic and early clinical complications during induction therapy for acute promyelocytic leukemia: A multicenter prospective cohort study

Jinjun Yang, Xin Zhang2, Baozhu Luo, MD3, Xiao Shuai4, Chenlu Yang, PhD5, Chuan He Sr, ????6, Liping Xie7, Xiaoou Huang8, Yang Dai9, Li Hou10, Yong Guo11, Jiazhuo Liu12, Jing Huang13, Xiao Jian14, Ya Zhang15, Yu Wu, MD16
1 West China Hospital of Sichuan University, Chengdu, China
2 West China Hospital of Sichuan University, Chengdu, China
3 West China Hospital of Sichuan University, Chengdu, China
4 West China Hospital of Sichuan University, Chengdu, China
5 West China Hospital of Sichuan University, Chengdu, China
6 West China Hospital of Sichuan University, Chengdu, China
7 West China Hospital of Sichuan University, Chengdu, China
8 West China Hospital of Sichuan University, Chengdu, China
9 West China Hospital of Sichuan University, Chengdu, China
10 West China Hospital of Sichuan University, Chengdu, China
11 West China Hospital of Sichuan University, Chengdu, China
12 West China Hospital of Sichuan University, Chengdu, China
13 Chengdu Second People’s Hospital of Sichuan University, Chengdu, China
14 Zigong First People's Hospital, Zigong, China
15 Mianyang Central Hospital, Mianyang, China
16 West China Hospital of Sichuan University, Chengdu, China

Background

Acute promyelocytic leukemia (APL) remains complicated by thrombohemorrhagic events and systemic deterioration during induction therapy despite modern treatment with all-trans retinoic acid and arsenic trioxide. Conventional risk classifications, based mainly on white blood cell and platelet counts, incompletely capture the coagulation activation, fibrinolytic dysregulation, and endothelial injury underlying these complications. We investigated whether baseline hemostatic and endothelial biomarkers were associated with early clinical complications and improved discrimination beyond conventional variables.

Methods

In this multicenter prospective observational cohort study, 120 patients with suspected APL were enrolled at 4 tertiary hematology centers in China between January 2023 and May 2026. Two patients whose diagnoses were revised to non-APL acute myeloid leukemia were excluded, leaving 118 patients with molecularly confirmed APL. Before induction therapy, plasma thrombin-antithrombin complex (TAT), plasmin-α2-plasmin inhibitor complex (PIC), thrombomodulin (TM), and tissue plasminogen activator-inhibitor complex (tPAIC) were measured. All patients received induction with all-trans retinoic acid and arsenic trioxide. Prespecified outcomes during induction included bleeding, thrombosis, differentiation syndrome (DS), and severe organ dysfunction. Multivariable logistic regression and receiver operating characteristic analyses evaluated independent associations and incremental discrimination. The study was approved by the institutional review boards or ethics committees of all participating centers (2019 Review No. 114).

Results

Among 118 patients, all 4 biomarkers were higher in patients with bleeding (TAT, P = 0.005; PIC, P = 0.003; TM, P < 0.001; tPAIC, P = 0.003), whereas PIC was higher in those with thrombosis (P = 0.011). TAT, PIC, and TM were higher in patients with DS (P = 0.002, P = 0.003, and P = 0.016, respectively), and PIC, TM, and tPAIC were higher in patients with severe organ dysfunction (P = 0.031, P < 0.001, and P < 0.001, respectively).

After adjustment for age, white blood cell count, platelet count, fibrinogen, and D-dimer, TM was independently associated with bleeding (adjusted odds ratio [aOR], 2.07; 95% confidence interval [CI], 1.13–3.78; P = 0.019), DS (aOR, 1.78; 95% CI, 1.01–3.12; P = 0.046), and severe organ dysfunction (aOR, 2.90; 95% CI, 1.39–6.05; P = 0.004), whereas PIC was independently associated with thrombosis (aOR, 3.26; 95% CI, 1.31–8.14; P = 0.011).

An exploratory biomarker-integrated score showed apparent areas under the curve (AUCs) of 0.719 for bleeding, 0.653 for thrombosis, 0.680 for DS, and 0.770 for severe organ dysfunction. Across low-, intermediate-, and high-score strata, event rates increased from 23.1% to 51.9% and 76.0% for bleeding (trend P < 0.001), from 35.9% to 51.9% and 72.0% for DS (trend P = 0.005), and from 10.3% to 27.8% and 64.0% for severe organ dysfunction (trend P < 0.001). Thrombotic events increased numerically from 7.7% to 13.0% and 24.0%, although the trend was not statistically significant (trend P = 0.070). Adding TM increased the AUC from 0.638 to 0.754 for bleeding (DeLong P = 0.018) and from 0.716 to 0.833 for severe organ dysfunction (DeLong P = 0.018), whereas adding PIC increased the AUC from 0.532 to 0.711 for thrombosis (DeLong P = 0.036).

Conclusions

Baseline hemostatic and endothelial biomarker profiling captured complementary thrombohemorrhagic and systemic risk in APL. TM was associated with bleeding, DS, and severe organ dysfunction, whereas PIC was associated with thrombosis. Biomarker-informed assessment may complement conventional clinical evaluation, but the exploratory score requires validation before clinical implementation.

Jinjun Yang: No relevant conflicts of interest to declare.